טוען...
The use of tafasitamab in diffuse large B-cell lymphoma
Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant (ASCT). Tafasitamab is a humanized monoclonal anti-CD19 antibody that has recently bee...
שמור ב:
| הוצא לאור ב: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8264734/ https://ncbi.nlm.nih.gov/pubmed/34285786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20406207211027458 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|